22:07 , Aug 14, 2019 |  BC Extra  |  Clinical News

Aug. 14 Clinical Quick Takes: Lynparza boosts ovarian cancer survival in first-line setting; plus Novavax, Gritstone and Solid

Lynparza extends PFS in first-line ovarian cancer  Lynparza olaparib plus bevacizumab as first-line maintenance therapy met the primary endpoint of significantly extending progression-free survival (PFS) vs. standard-of-care bevacizumab alone in advanced ovarian cancer patients in...
02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
23:22 , Jul 8, 2019 |  BC Extra  |  Company News

Management tracks: Gritstone, ICMRA, Anika, Lyra

Neoantigen immunotherapy company Gritstone Oncology Inc. (NASDAQ:GRTS) hired Vijay Yabannavar as EVP of manufacturing and technical operations. He was VP of global technical operations at Merck and Co. Inc. (NYSE:MRK). The International Coalition of Medicines...
18:57 , Apr 25, 2019 |  BC Extra  |  Financial News

Gritstone raises $75M in follow-on as second neoantigen immunotherapy heads to clinic

Days after saying it plans to accelerate its second neoantigen immunotherapy into the clinic, Gritstone has raised $74.8 million in a follow-on. Gritstone Oncology Inc. (NASDAQ:GRTS) sold $6.5 million shares at $11.50 in the deal,...
22:22 , Apr 22, 2019 |  BC Innovations  |  Translation in Brief

Oncogenic gene fusions can create neoantigens

Memorial Sloan Kettering Cancer Center researchers have identified gene fusions as a source of cancer neoantigens that could be targeted by immunotherapy. As companies develop immunotherapies against neoantigens, research is increasingly looking beyond point mutations...
19:35 , Jan 18, 2019 |  BioCentury  |  Emerging Company Profile

Achilles’ truncal neoantigens

Achilles Therapeutics Ltd. is developing a personalized T cell therapy that uses “truncal” neoantigens expressed in all tumor cells to drive T cells selected from tumor-infiltrating lymphocytes (TILs). Neoantigen discovery is fueling a burst of...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
13:42 , Jan 3, 2019 |  BC Innovations  |  Distillery Techniques

Assays and screens; other

TECHNOLOGY: Cellular assays; computational models A computational method to predict HLA peptide presentation could help identify neoantigens for cancer immunotherapy. The deep learning model was trained on a data set to identify the relationships between...
07:01 , Dec 18, 2018 |  BC Extra  |  Tools & Techniques

Gritstone showcases mass spec-based neoantigen discovery platform

Gritstone Oncology Inc. (NASDAQ:GRTS) unveiled the inner workings of its mass spectrometry-based neoantigen identification platform, EDGE, in a Nature Biotechnology study published Monday. Results from the paper suggest building a machine-learning algorithm based on human...